218. Alport syndrome
[
8 clinical trials,
15 drugs（DrugBank:
8 drugs),
5 target genes / 25 target pathways ]
Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03749447 | March 8, 2019 | 2 September 2019 | An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) | An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease | Chronic Kidney Diseases;Alport Syndrome | Drug: Bardoxolone methyl | Reata Pharmaceuticals, Inc. | Recruiting | 12 Years | 65 Years | All | 180 | Phase 3 | United States | |
| 2 | JPRN-UMIN000032448 | 2018/05/01 | 7 October 2019 | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL | Alport Syndrome | Drug: Bardoxolone Methyl Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status. Dosing period is up to 2 years. Drug: Placebo Oral Capsule Capsule containing an inert placebo is administrated up to 2 years. | Reata Pharmaceuticals, Inc | Not Recruiting | 12years-old | 70years-old | Male and Female | 180 | Not selected | Japan,North America,Australia,Europe | |
| 3 | NCT03373786 | December 22, 2017 | 3 June 2019 | A Study of RG-012 in Subjects With Alport Syndrome | A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome | Alport Syndrome | Drug: RG012 | Genzyme, a Sanofi Company | Not recruiting | 18 Years | 65 Years | All | 4 | Phase 1 | United States | |
| 4 | NCT02855268 | November 7, 2017 | 11 November 2019 | Study of SAR339375 in Patients With Alport Syndrome | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of SAR339375 for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome | Alport's Syndrome | Drug: SAR339375;Drug: Placebo | Genzyme, a Sanofi Company | Recruiting | 18 Years | 55 Years | All | 45 | Phase 2 | United States | |
| 5 | NCT03019185 | March 2, 2017 | 26 November 2018 | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome | Alport Syndrome | Drug: Placebo Oral Capsule;Drug: Bardoxolone Methyl | Reata Pharmaceuticals, Inc. | Not recruiting | 12 Years | 60 Years | All | 187 | Phase 2/Phase 3 | United States;Australia;France;Germany;Japan;Puerto Rico;Spain;United Kingdom;Canada | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01485978 | March 2012 | 16 December 2017 | Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome | Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome | Renal Insufficiency, Chronic | Drug: Ramipril;Drug: placebo to ramipril | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | University Medical Center Goettingen;German Federal Ministry of Education and Research | Not recruiting | 24 Months | 18 Years | All | 66 | Phase 3 | Germany |
| 7 | NCT00309257 | January 2004 | 19 February 2015 | Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome | Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome | Alport Syndrome | Drug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and Fluvastatin | Mario Negri Institute for Pharmacological Research | Not recruiting | 15 Years | 70 Years | Both | 9 | Phase 2 | Italy | |
| 8 | NCT02378805 | July 1995 | 11 February 2019 | European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome | European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies | Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane Disease;Familial Benign Hematuria | Drug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol | University Hospital Goettingen | Society for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive Medicine | Recruiting | N/A | N/A | All | 500 | N/A | Germany |